On average, people who were a part of a study lost weight gradually over the course of about 1 year and 3 months, and then stabilized around 10% below their starting weight at the 4-year mark.The findings are important because questions have lingered about the impacts of taking the drug long-term. The active ingredient in Wegovy is called semaglutide, which is the same active ingredient as in the diabetes drug Ozempic. Both are made by the Danish drug company Novo Nordisk.After taking the drug for 2 years, 44% of people had lost 10% of their body weight or more, while nearly one-third of those in the study lost less than 5% of their body weight.